![Alessio Cortellini: Immune-suppressive role of RANKL in patients with NSCLC treated with ICI](https://oncodaily.com/pub/uploads/2024/06/Alessio-Cortellini-1-e1719488819240.png)
Photo taken from policlinicocampusbiomedico.it
Jun 29, 2024, 14:51
Alessio Cortellini: Immune-suppressive role of RANKL in patients with NSCLC treated with ICI
Alessio Cortellini, Assistant Professor at Campus Bio-Medico University of Rome, shared a post by Journal for ImmunoTherapy of Cancer, on X:
“Happy to share this work out on Journal for ImmunoTherapy of Cancer on the potential immune-suppressive role of RANKL in patients with NSCLC treated with ICI. Entirely thought through and performed at UCBM.”.
Quoting Journal for ImmunoTherapy of Cancer‘s post:
“New JITC article: Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).”
Read further.
Source: Alessio Cortellini/X and Journal for ImmunoTherapy of Cancer/X